The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period (2019–2024). The growth of the women’s healthcare market is primarily due to the increasing initiatives taken by the government to curb population growth. The growth of this market can be attributed to the rising incidence of chronic health conditions among women, the demand for contraceptives to prevent unintended pregnancies, and the growing focus on product R&D.
On the other hand, reluctance shown by women to adopt contraceptives due to the anxiety of subsequent side effects caused by birth control pills is the prime factor that challenges the growth of the market.
To know about the assumptions considered for the study download the pdf brochure
The women’s healthcare market is a highly diversified and competitive market, with several large and emerging players. The prominent players in this market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly and Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US). The players present in the market focus on providing effective products to cater to the unmet needs of customers, increase profitability, and gain a competitive edge in the market.
Amgen (US) is one of the leading providers of the women’s healthcare market. The company’s sales and marketing activities are greatly focused on the US and Europe. The company provides Prolia and Xgeva for the treatment of osteoporosis in postmenopausal women. These drugs have shown a year-on-year double-digit value gain as well as volume growth, and constitute the largest share of the women’s healthcare market. Amgen’s EVENITY, meant for the treatment of osteoporosis in postmenopausal women, is also in phase 3 of development. It is being developed in collaboration with UCB (Belgium). The company’s high brand recognition and focus on product innovation have helped it to maintain its foothold in the market.
Eli Lilly and Company (US)
Eli Lilly is one of the leading players in the women’s healthcare market. The company provides EVISTA and FORTEO for the treatment of postmenopausal osteoporosis. The company’s vast geographical presence is one of its key strengths and gives the company a competitive advantage over other players. The company operates in around 120 countries across North America, Latin America, Europe, Eastern Europe, the Middle East, Africa, and the Asia Pacific, with manufacturing units located in 13 countries. The company mainly focuses on product innovation.
Bayer AG (US)
Bayer AG is one of the prominent players in the women’s healthcare market. Its leading position can be attributed to its strong presence across the globe and extensive product portfolio in this market. The company is a provider of effective and bestselling women’s healthcare products, such as Mirena, Kyleena, Yaz/Yasmin/Yasminelle, and Visanne. For secured long-term growth in the market, the company focuses on investing heavily in R&D in areas that require innovation. Levonorgestrel (progestin) + indomethacin (NSAID) combi IUS (contraceptive) and Vilaprisan (S-PRM) (endometriosis) are two of the company’s drug candidates—in Phase II clinical testing—in the women’s health sector.
Furthermore, the company focuses on harnessing digital technologies that include telemedicine and AI-driven diagnostics and treatment. This is one of the key strategies adopted by the company to propel the growth of its pharmaceuticals segment.
Merck & Co (US)
Merck & Co, Inc. is one of the largest pharmaceutical companies worldwide. The company provides Nuvaring, a hormonal contraceptive device for women. The product recorded significant sales in 2018—USD 902 million, as compared to USD 761 million in 2017 (Source: Merck Annual Report).
Some of the key strengths of the company include its extensive distribution network across healthcare markets, significant R&D investments, and strong brand recognition. In order to sustain its hold in the market, the company invests heavily in R&D—for instance, its investment in 2018 was USD 9.8 billion. The company has state-of-the-art production sites located across the globe that comply with cGMP standards and have an unblemished FDA track record.
Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE